'Breakthrough' mRNA cancer drug curbs melanoma in large trial

US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough." Researchers have for years been trying to apply mRNA treatments against cancer, but this was the first time such a drug showed positive results in a large, late-stage clinical trial.